Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 24, 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure changes.
- Shares Repurchased: 1,000,000 ordinary shares of 25 pence each.
- Repurchase Date: August 24, 2011.
- Price Range: Highest price paid was 1,325.5 pence per share; lowest price paid was 1,291 pence per share.
- Treasury Shares Held: 502,996,816 shares (representing 9.01% of total issued share capital and 9.90% of total voting rights).
- Shares in Issue: 5,081,776,480 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's issued share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the total number of shares in issue (excluding Treasury shares) stands at 5,081,776,480, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,081,776,480) for accurate calculation of ownership percentages under disclosure rules.
- Confirm the updated Treasury share count (502,996,816) and its impact on voting rights (9.90%).
- Review the share repurchase price range (1,291 to 1,325.5 pence) to assess the cost of capital return to shareholders.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial metrics.